FDA 483 - ten23 health Valais AG - February 28, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
The FDA inspected ten23 health Valais AG, a drug product manufacturer in Visp, Switzerland, and found significant deficiencies in aseptic processing, environmental monitoring, quality control, and CAPA effectiveness. Observations included inadequate procedures to prevent microbiological contamination, persistent mold issues in cleanrooms, and insufficient visual inspection qualification for drug products. These issues indicate a high risk of product contamination and quality control failures.
ID · c195eb48-c4e3-453a-ae5a-65a7cb9e397f